This proposal outlines a multidisciplinary effort by four principal investigators to continue development of a series of cyclic and linear conformationally constrained peptide analogues which have high receptor specificity high agonist or antagonist biological activities, high stability in vivo, and prolonged biological activity at kappa (kappa) opioid receptors. This multidisciplinary approach combines modern computer assisted molecular modeling, organic amino acid and peptide chemistry, conformational analysis and molecular mechanics and dynamics calculations, and biochemical, biophysical, physiological and pharmacological studies.
The specific aims of this investigation include: a) continues development in the design, synthesis, and evaluation of novel peptides and peptide mimetics derived from dynorphin and related peptides which possess high kappa opioid receptor potency and specificity; b) comprehensive examination of the potency and specificity of all new ligands for kappa vs. mu and delta opioid receptors using radioligand binding techniques. The most selective and potent ligands will be radiolabeled to high specific activity and used in extensive radioligand binding studies and for receptor localization using autoradiography; c) opioid agonist or antagonist activities will be evaluated in vitro using the GPI, MVD, LVP and HVD assays to establish receptor selectivity and potency; d) in vivo kappa receptor properties will be evaluated with the most selectivity compounds using among other assays, the mouse abdominal stretch test following intrathecal administration, and the standard mouse hot plate test; 5) careful examination of the conformational and dynamic properties of the most potent and selective analogues using 1D and 2D nuclear magnetic resonance spectroscopy, molecular mechanics calculations, and other biophysical techniques; and 6) using all of the above results of the design and synthesis of novel compounds with more potent and selective biological activities, and to test conformational models proposed for kappa receptor selective ligands. The long term goal of this research is to develop an understanding of the physiological roles of the kappa opioid receptor in comparison to other opioid receptors, and to develop ligands for the kappa receptors that can be used for the treatment of disease.

National Institute of Health (NIH)
National Institute on Drug Abuse (NIDA)
Research Project (R01)
Project #
Application #
Study Section
Drug Abuse Biomedical Research Review Committee (DABR)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Arizona
Schools of Arts and Sciences
United States
Zip Code
Bird, M F; Vardanyan, R S; Hruby, V J et al. (2015) Development and characterisation of novel fentanyl-delta opioid receptor antagonist based bivalent ligands. Br J Anaesth 114:646-56
Soloshonok, Vadim A; Cai, Chaozhong; Yamada, Takeshi et al. (2005) Michael addition reactions between chiral equivalents of a nucleophilic glycine and (S)- or (R)-3-[(E)-enoyl]-4-phenyl-1,3-oxazolidin-2-ones as a general method for efficient preparation of beta-substituted pyroglutamic acids. Case of topographically cont J Am Chem Soc 127:15296-303
Soloshonok, Vadim A; Ueki, Hisanori; Tiwari, Rohit et al. (2004) Virtually complete control of simple and face diastereoselectivity in the Michael addition reactions between achiral equivalents of a nucleophilic glycine and (S)- or (R)-3-(E-enoyl)-4-phenyl-1,3-oxazolidin-2-ones: practical method for preparation of beta J Org Chem 69:4984-90
Soloshonok, V A; Cai, C; Hruby, V J et al. (2000) Rational design of highly diastereoselective, organic base-catalyzed, room-temperature Michael addition reactions. J Org Chem 65:6688-96
Okayama, T; Burritt, A; Hruby, V J (2000) 4-Alkoxy-2-hydroxybenzaldehyde (AHB): a versatile aldehyde linker for solid-phase synthesis of C-terminal modified peptides and peptidomimetics. Org Lett 2:1787-90
Ko, M C; Willmont, K J; Burritt, A et al. (2000) Local inhibitory effects of dynorphin A-(1-17) on capsaicin-induced thermal allodynia in rhesus monkeys. Eur J Pharmacol 402:69-76
Soloshonok, V A; Cai, C; Hruby, V J (2000) (S)- or (R)-3-(E-enoyl)-4-phenyl-1,3-oxazolidin-2-ones: ideal Michael acceptors to afford a virtually complete control of simple and face diastereoselectivity in addition reactions with glycine derivatives. Org Lett 2:747-50
Tang, Q; Lynch, R M; Porreca, F et al. (2000) Dynorphin A elicits an increase in intracellular calcium in cultured neurons via a non-opioid, non-NMDA mechanism. J Neurophysiol 83:2610-5
Hruby, V J; Agnes, R S (1999) Conformation-activity relationships of opioid peptides with selective activities at opioid receptors. Biopolymers 51:391-410
Tang, Q; Gandhoke, R; Burritt, A et al. (1999) High-affinity interaction of (des-Tyrosyl)dynorphin A(2-17) with NMDA receptors. J Pharmacol Exp Ther 291:760-5

Showing the most recent 10 out of 44 publications